Subventions financées

Challenge: ALS (amyotrophic lateral sclerosis) is an incurable and invariably fatal motor neuron (MN) disease.

Glioblastoma is one of the most aggressive brain cancers, with very few treatment options and a poor survival rate.

Challenge: Delivery of therapeutic proteins to the brain has been a longstanding barrier to CNS drug
development.

The increasing prevalence of anxio-depressive disorders worldwide suggests that current therapeutic strategies are insufficient in tackling this global health concern.

The Challenge: Current therapies for treating a number of mental health disorders – depression, anxiety,
and PTSD, among them – adequately treat only a small fraction of afflicted patients.

“Vascular pathology, such as loss of neurovascular coupling and disruption of the blood-brain barrier (BBB), has been documented in Huntington’s disease (HD).

Psychedelic drugs, known for their profound effects on perception, are showing promise as rapid and long-lasting treatments for depression.

Caring for a family member with a neurodevelopmental disability (NDD) can be challenging, often leading to high levels of anxiety and depression.

In Alzheimer’s disease (AD), the pathogenic amyloid-beta protein accumulates in the brain parenchyma and vessel walls.

Depression is a leading cause of disability, with a large proportion of treatment-resistant patients. Recent studies have implicated reduced brain inhibition in human depression from a specific neuron type (SST), and new pharmacology boosting this reduced inhibition led to antidepressant and pro-cognitive effects in rodents.